Drospirenone And Ethinyl Estradiol Kit
Product Images NDC 68462-720

This appears to be a medication label, specifically for Drospirenone and Ethinyl Estradiol Tablets, USP. The label includes dosage information (3mg/0.02mg) and days of the week (WED, THUR, FRI). It also notes that this is "WEEK 3" and that "WEEK 2 START" has already occurred, with "WEEK 4" in the future.*

This is a description of a contraceptive drug package. The carton size, artwork size, and contents are specified. The package contains one carton with three pouches, and each pouch contains one blister of 28 tablets. The tablets come in different colors, with 24 brown to reddish-brown tablets containing 3 mg of drospirenone and 0.02 mg of ethinyl estradiol, and four white to off-white inert tablets. The usual dosage is one tablet daily for 28 consecutive days per menstrual cycle. The manufacturer provides an informational piece in each unit for the patient. The product is intended to prevent pregnancy but does not protect against HIV infection or other sexually transmitted diseases. Contact information for the manufacturer is provided.*

This text describes various methods of birth control and their effectiveness in preventing pregnancies. It lists the different number of pregnancies per every 100 women per year for each method. The methods listed include implants, injections, intrauterine devices, sterilization, birth control pills, skin patch, vaginal ring with hormones, condoms, diaphragm, no sex during the most fertile days of the monthly cycle, spermicide, withdrawal, and no birth control.*

The text appears to be a list of various studies, with some mentioning of Hazard Ratio, Rate Ratio, and Odds Ratio. The studies are from different countries and some are funded by the FDA. They include prospective cohort studies, case-control studies, and non-fatal idiopathic cases. There is not enough information to provide a specific description of what the studies are about.*

This appears to be a chart or table displaying ranges and numbers of blood clot incidents in non-pregnant and postpartum women. The data includes a note explaining that the pregnancy data is based on actual pregnancy duration and a model is used to estimate the rate.*

This text appears to be presenting a list of studies and their results regarding the use of Combined Oral Contraceptives (COC) among women. Some studies compare Ever-use vs. Never-use of COC, while others compare Current-use vs. Never-use of COC. The text includes various statistical measures such as Effect Estimate, OR, RR, and HR, to indicate the relative risks associated with the different methods of analysis. However, it is difficult to draw any further conclusions without additional context or information.*

The text is a company name: "Glenmark".*

This is not available to generate a useful description as it lacks context and information.*

This text provides information about the number of women who experienced blood clots during pregnancy and postpartum. It includes ranges for non-pregnant and non-COC users, as well as data based on an assumption of pregnancy duration of nine months. The number of women with a blood clot is given out of 10,000 women years (WY).*